Search Results - "Goetze, T.O."

New perspectives in biliary tract cancers by Goetze, T.O., Roderburg, C., Friedrich, F.W., Trojan, J.

“…Biliary tract cancer (BTC) is a rare but highly lethal malignancy. Despite recent advances in diagnosis and treatment, the overall prognosis remains dismal,…”
Get full text

SAGA—a phase Ib/II single-arm, multicenter study of sacituzumab govitecan for patients with metastatic esophagogastric adenocarcinoma by B. Kobitzsch, G. Stocker, U.T. Hacker, S. Junge, C. Pauligk, S.-E. Al-Batran, T.O. Goetze, F. Lordick

“…Background: Treatment of metastatic and locally advanced unresectable esophagogastric adenocarcinoma (EGA) after first-line therapy has limited efficacy…”
Get full text

107P Comprehensive genomic profiling of “The German-registry of incidental gallbladder carcinoma” cases by Agaoglu, N.B., Kochen, L., Müller, D.W., Vortmeyer, D., Habibzada, T., Al-Batran, S-E., Goetze, T.O.

Get full text

1042P INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas by Atmaca, A., Müller, D.W., Habibzada, T., Schaaf, M., Klagges, J., Eickhoff, R., Jäger, E., Al-Batran, S-E., Goetze, T.O.

Get full text

49P Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study by Goetze, T.O., Stein, A., Lorenzen, S., Habibzade, T., Goekkurt, E., Herhaus, P., Sookthai, D., Ihrig, K., Pauligk, C., Al-Batran, S-E.

Get full text

1535P Paclitaxel + ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the oesophagus, refractory or intolerant to combination therapy with fluoropyrimidine and platinum-based drugs: Final results from the randomized phase II IKF-S627/RAMOS trial of the AIO by Scheck, M., Goetze, T.O., Ettrich, T.J., Schmalenberg, H., Clemens, M.R., Mahlberg, R.J.C., Heeg, S., Kanzler, S., Hapke, G., Thuss-Patience, P.C., Kestler, A., Treschl, A., Frost, G.A., Heidel, S., Schiemer, M., Junge, S., Pauligk, C., Al-Batran, S-E., Lorenzen, S.

Get full text

1032P Safety data from stratum D of the phase I INSIGHT platform trial evaluating feasibility of IMP321 (LAG-3Ig protein, eftilagimod alpha) combined with avelumab in advanced stage solid tumour entities by Goetze, T.O., Müller, D.W., Rafiyan, M-R., Kiselicki, D., Habibzade, T., Eickhoff, R., Jäger, E., Al-Batran, S-E.

Get full text

985P Advanced safety and efficacy data from stratum D of the phase I INSIGHT platform trial evaluating feasibility and safety of eftilagimod alpha combined with avelumab in advanced solid tumors by Goetze, T.O., Daniel, M.W., Rafiyan, M-R., Kiselicki, D., Habibzade, T., Schaaf, M., Eickhoff, R., Jaeger, E., Al-Batran, S-E.

Get full text

1619P Health-related quality of life with nalirifox versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): EORTC QLQ-C30 results from the NAPOLI 3 trial by Melisi, D., Macarulla, T., de la Fouchardiere, C., Pazo Cid, R.A., Chandana, S., Dean, A., Kiss, I., Lee, W., Goetze, T.O., Van Cutsem, E., Paulson, A.S., Bekaii-Saab, T., Pant, S., Hubner, R., Xiao, Z., Zhang, L., Benzaghou, F.M., O'Reilly, E.M., Wainberg, Z.A.

Get full text

1033P The phase I INSIGHT platform trial: Strata A and B evaluating feasibility of intratumoral and intraperitoneal IMP321 (soluble LAG-3 protein, eftilagimod alpha) in advanced solid tumours by Al-Batran, S-E., Müller, D.W., Rafiyan, M-R., Kiselicki, D., Habibzade, T., Brignone, C., Eickhoff, R., Jäger, E., Goetze, T.O.

Get full text

LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: Final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group by Perkhofer, L., Striefler, J.K., Sinn, M., Opitz, B., Goetze, T.O., Gallmeier, E., Fischer von Weikersthal, L., Jacobasch, L., Waldschmidt, D., Niedermeier, M., Sohm, M., Sookthai, D., Berger, A., Beutel, A., Seufferlein, T., Ettrich, T.J.

Get full text

Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of “The German- Registry” by Goetze, T.O., Al-Batran, S.-E.

Get full text

1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2 positive resectable esophagogastric adenocarcinoma by Al-Batran, S-E., Haag, G.M., Ettrich, T.J., Borchert, K., Kretzschmar, A., Teschendorf, C., Siegler, G.M., Ebert, M., Goekkurt, E., Welslau, M.K., Mahlberg, R.J.C., Homann, N., Pink, D., Bechstein, W.O., Reichardt, P., Gaiser, T., Sookthai, D., Pauligk, C., Goetze, T.O., Hofheinz, R.D.

Get full text

Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO by Lorenzen, S., Pauligk, C., Goetze, T.O., Riera Knorrenschild, J., Goekkurt, E., Kullmann, F., Pink, D., Ettrich, T.J., Homann, N., Angermeier, S., Thuss-Patience, P.C., Lindig, U., Bitzer, M., Dechow, T., Schuch, G., Schmalenberg, H., Junge, S., Hofheinz, R.D., Al-Batran, S.-E.

Get full text

835TiP - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction: Moonlight, a randomized phase II trial of the German Gastric Group of the AIO by Lorenzen, S., Pauligk, C., Goetze, T.O., Riera Knorrenschild, J., Goekkurt, E., Kullmann, F., Pink, D., Ettrich, T.J., Homann, N., Angermeier, S., Thuss-Patience, P.C., Lindig, U., Bitzer, M., Dechow, T., Schuch, G., Schmalenberg, H., Junge, S., Hofheinz, R.D., Al-Batran, S.-E.

“…The majority of patients (pts) with gastroesophageal cancer present with inoperable or metastatic disease and there is a strong need for efficient and…”
Get full text

841TiP - Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK by Al-Batran, S.-E., Pauligk, C., Hofheinz, R.D., Lorenzen, S., Wicki, A., Siebenhuener, A.R., Schenk, M., Thuss-Patience, P.C., Kretzschmar, A., Bolling, C., Eigendorff, E., Angermeier, S., Pink, D., Geissler, M., Goekkurt, E., Schmalenberg, H., Waberer, L., Talbot, J.J., Goetze, T.O., Homann, N.

“…Perioperative FLOT chemotherapy has become a standard of care for locally advanced, resectable gastric cancer and adenocarcinoma of the GEJ. However, patient…”
Get full text

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK by Al-Batran, S.-E., Pauligk, C., Hofheinz, R.D., Lorenzen, S., Wicki, A., Siebenhuener, A.R., Schenk, M., Thuss-Patience, P.C., Kretzschmar, A., Bolling, C., Eigendorff, E., Angermeier, S., Pink, D., Geissler, M., Goekkurt, E., Schmalenberg, H., Waberer, L., Talbot, J.J., Goetze, T.O., Homann, N.

Get full text

Home parenteral nutrition (HPN) using individually compounded PN via A 7/8/9-Multi-chamber system versus PN via 2/3-chamber bags in subjects with metastatic or localized solid tumors requiring HPN - The IKF-010 Pekannuss trial by Al-Batran, S.-E., Roetzer, I., Wohn, L., Blau, W., Zander, T., Luley, K.B., Ivanyi, P., Hofheinz, R.-D., Groschek, M., Kreiss-Sender, J., Baur, C., Wolff, T., Wenning, B., Decker-Baumann, C., Bouymayan, S., Sookthai, D., Schaaf, M., Riedel, J., Goetze, T.O., Haag, G.M.

Get full text

Phase III KEYNOTE-585 study of chemotherapy (Chemo) + pembrolizumab (Pembro) vs chemo + placebo as neoadjuvant/adjuvant treatment for patients (Pts) with gastric or gastroesophageal junction (G/GEJ) cancer by Bang, Y.-J., Van Cutsem, E., Fuchs, C.S., Ohtsu, A., Tabernero, J., Ilson, D.H., Hyung, W.J., Strong, V.E., Goetze, T.O., Yoshikawa, T., Tang, L.H., Hwang, P.M.T., Adelberg, D., Shitara, K.

Get full text

A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncology by Al-Batran, S.-E., Mueller, D.W., Rafiyan, M.-R., Kiselicki, D., Atmaca, A., Habibzada, T., Mueller, C., Brignone, C., Triebel, F., Loose, M., Schaaf, M., Sookthai, D., Eickhoff, R., Jaeger, E., Goetze, T.O.

“…Eftilagimod alpha (efti) is a major histocompatibility complex class II agonist activating antigen-presenting cells which leads to greater systemic type 1 T…”
Get full text